Influence of different polymers on crystallization tendency and dissolution behavior of cilnidipine in solid dispersions

Drug Development and Industrial Pharmacy

Volumn 40, Issue 4, 2014, Pages 441-451

  Chen, Chen ^a   Xie, Xiabing ^a   Li, Yang ^a   Zhou, Chen ^a   Song, Yang ^b   Yan, Zhixiang ^a   Yang, Xinghao ^a  

^a NANJING NORMAL UNIVERSITY   (China)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Crystallization; Dissolution; Hydrogen bond; Polymer; Solid dispersion

Indexed keywords

1 VINYL 2 PYRROLIDINONE; CILNIDIPINE; POLYMER; POVIDONE; SOLUPLUS; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; CRYSTALLOGRAPHY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DISSOLUTION; DRUG STABILITY; DRUG STRUCTURE; FOURIER TRANSFORM INFRARED PHOTOACOUSTIC SPECTROSCOPY; HYDROGEN BOND; IN VITRO STUDY; MICROSCOPY; SCANNING ELECTRON MICROSCOPY; SOLID STATE; THERMAL ANALYSIS; THERMOGRAPHY; X RAY DIFFRACTION;

CALCIUM CHANNEL BLOCKERS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DIHYDROPYRIDINES; DRUG CARRIERS; DRUG STABILITY; DRUG STORAGE; HYDROGEN BONDING; POLYETHYLENE GLYCOLS; POLYMERS; POLYVINYLS; POVIDONE; PYRROLIDINES; SOLUBILITY; TIME FACTORS; VINYL COMPOUNDS;

EID: 84896705229     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.767825     Document Type: Article

References (72)

1. Yoshimoto R, Dohmoto H, Yamada K, Goto A. Prolonged inhibition of vascular contraction and calcium influx by the novel 1,4- dihydropyridine calcium antagonist cinaldipine (FRC-8653). Jpn J Pharmacol 1991;56:225-9.
2. Nakashima M, Kou M, Hashitani H, et al. Actions of FRC-8653 on smooth muscle cells of the rabbit mesenteric artery. Jpn J Pharmacol 1991;57:51-61.
3. Noguchi K, Matsuzaki T, Koyama T, Sakanashi TIM. Comparison of haemodynamic responses to cinaldipine and nicardipine in an experimental model of acute congestive heart failure. Clin Exp Pharmacol Physiol 1998;25:541-7.
4. Yagi S, Goto S, Yamamoto T, et al. Effect of cinaldipine on insulin sensitivity in patients with essential hypertension. Hypertens Res 2003;26:383-7.
5. Sinha S, Baboota S, Ali M, et al. Solid dispersion: an alternative technique for bioavailability enhancement of poorly soluble drugs. J Disper Sci Technol 2009;30:1458-73.
6. Amidon GL, Lennemas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20.
7. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47-60.
8. Gowariker VR, Viswanathan NV, Sreedhar J. Polymer science. New Delhi, India: New Age; 1986.
9. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997; 86:1-12.
10. Smikalla MM, Urbanetz NA. The influence of povidone K17 on the storage stability of solid dispersions of nimodipine and polyethylene glycol. Eur J Pharm Biopharm 2007;66:106-12.
11. Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 1997;14:1691-98.
12. Miyazaki T, Yoshioka S, Aso Y, Kojima S. Ability of polyvinylpyrrolidone and polyacrylic acid to inhibit the crystallization of amorphous acetaminophen. J Pharm Sci 2004; 93:2710-17.
13. Khougaz K, Clas S-DE. Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers. J Pharm Sci 2000;89:1325-34.
14. Weuts I, Kempen D, Decorte A, et al. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64. Eur J Pharm Sci 2005;25:313-20.
15. Mooter GVD, Wuyts M, Blaton N, et al. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci 2001;12:261-9.
16. Oksanen CA, Zografi G. The relationship between the glass transition temperature and water vapor absorption by poly(vinylpyrrolidone). Pharm Res 1990;7:654-7.
17. Aso Y, Yoshioka S, Zhang J, Zografi G. Effect of water on the molecular mobility of sucrose and poly(vinylpyrrolidone) in a colyophilized formulation as measured by C-13-NMR relaxation time. Chem Pharm Bull 2002;50:822-6.
18. Gupta P, Thillagavathi R, Chakraborti AK, Bansal AK. Role of molecular interaction in stability of celecoxib-PVP amorphous systems. Mol Pharm 2005;2:384-91.
19. Abe Y, Arahori T, Naruse A. Crystallization of calcium metaphosphate glass below the glass transition temperature. J Am Ceram Soc 1976;59:487-90.
20. Yoshioka M, Hancock BC, Zografi G. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature. J Pharm Sci 1994;83:1700-5.
21. Matsumoto T, Zografi G. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(- vinylpyrrolidone-co-vinylacet-ate) in relation to indomethacin crystallization. Pharm Res 1999;16:1722-8.
22. Ishida H, Wu TA, Yu LA. Sudden rise of crystal growth rate of nifedipine near Tg without and with polyvinylpyrrolidone. J Pharm Sci 2007;96:1131-8.
23. Konno H, Taylor LS. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci 2006;95:2692-705.
24. Crowley KJ, Zografi G. The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state. Pharm Res 2003; 20:1417-22.
25. Taylor LS, Zografi G. Sugar-polymer hydrogen bond interactions in lyophilized amorphous mixtures. J Pharm Sci 1998;87:1615-21.
26. Kaushal AM, Chakraborti AK, Bansal AK. FTIR studies on differential intermolecular association in crystalline and amorphous states of structurally related non-steroidal anti-inflammatory drugs. Mol Pharm 2008;5:937-45.
27. Tong P, Zografi G. A study of amorphous molecular dispersions of indomethacin and its sodium salt. J Pharm Sci 2001;90:1991-2004.
28. Tang XLC, Pika MJ, Taylor LS. A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers. Pharm Res 2002; 19:477-83.
29. Van Eerdenbrugh B, Baird JA, Taylor LS. Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation- classification and comparison with crystallization tendency from undercooled melts. J Pharm Sci 2010;99:3826-38.
30. Eerdenbrugh BV, Taylor LS. Small scale screening to determine the ability of different polymers to inhibit drug crystallization upon rapid solvent evaporation. Mol Pharm 2006;7:1328-37.
31. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123-33.
32. Moore JW, Planner HH. Mathematical comparison of dissolution profiles. Pharm Technol 1996;20:64-74.
33. Papageorgiou GZ, Papadimitriou S, Karavas E, et al. Improvement in chemical and physical stability of fluvastatin drug through hydrogen bonding interactions with different polymer matrices. Curr Drug Deliv 2009;6:101-12.
34. Kanaze FI, Kokkalou E, Niopas I, et al. Dissolution enhancement of flavonoids by solid dispersion in PVP and PEG matrixes: a comparative study. J Appl Polym Sci 2006;102:460-71.
35. Rumondor ACF, Taylor LS. Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture. Mol Pharm 2010;7:477-90.
36. Rumondor ACF, Marsac PJ, Stanford LA, Taylor LS. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. Mol Pharm 2009;6:1492-505.
37. Mukharya A, Chaudhary S, Mansuri N, Misra AK. Solid-state characterization of lacidipine/PVP K(29/32) solid dispersion primed by solvent co-evaporation. Int J Pharm Invest 2012;2:90-6.
38. Gorajana A, Rajendran A, Dua K, et al. Preparation, characterization, and in vitro evaluation of nitrendipine solid dispersions. J Disper Sci Technol 2012;33:676-84.
39. Hirasawa N, Ishise S, Miyata H, Danjo K. Physicochemical characterization and drug release studies of nilvadipine solid dispersions using water-insoluble polymer as a carrier. Drug Dev Ind Pharm 2003;29:339-44.
40. Chutimaworapan S, Ritthidej GC, Yonemochi E, et al. Effect of water-soluble carriers on dissolution characteristics of nifedipine solid dispersions. Drug Dev Ind Pharm 2000;26:1141-50.
41. Bandarkar FS, Vavia PR. An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in betacyclodextrin. Drug Dev Ind Pharm 2011;37:1318-28.
42. Aggarwal AK, Singh S. Physicochemical characterization and dissolution study of solid dispersions of diacerein with polyethylene glycol 6000. Drug Dev Ind Pharm 2011;37:1181-91.
43. Fu JJ, Xu LS, Wang XL, et al. Nimodipine (NM) tablets with high dissolution containing NM solid dispersions prepared by hot-melt extrusion. Drug Dev Ind Pharm 2001;37:934-44.
44. He HB, Yang R, Tang X. In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion. Drug Dev Ind Pharm 2010;36:681-7.
45. Garg A, Singh S, Rao VU, et al. Solid state interaction of raloxifene HCl with different hydrophilic carriers during co-grinding and its effect on dissolution rate. Drug Dev Ind Pharm 2009;35:455-70.
46. Liu H, Zhou LL, Wei LL, et al. Preparation of budesonide-poly (ethylene oxide) solid dispersions using supercritical fluid technology. Drug Dev Ind Pharm 2007;33:959-66.
47. Chen SJ, Zhu JB, Ma FQ, et al. Preparation and characterization of solid dispersions of dipyridarmole with a carrier copolywidonum Plasdone (R) S-630. Drug Dev Ind Pharm 2007;33:888-99.
48. Ren FZ, Jing QF, Tang YH, et al. Characteristics of bicalutamide solid dispersions and improvement of the dissolution. Drug Dev Ind Pharm 2006;32:967-72.
49. Li L, AbuBaker O, Shao ZZJ. Characterization of poly(ethylene oxide) as a drug carrier in hot-melt extrusion. Drug Dev Ind Pharm 2006;32:991-1002.
50. El-Badry M, Fathy M. Enhancement of the dissolution and permeation rates of meloxicam by formation of its freeze-dried solid dispersions in polyvinylpyrrolidone K-30. Drug Dev Ind Pharm 2006;32:141-50.
51. Fouad EA, EL-Badry M, Mahrous GM, et al. The use of spraydrying to enhance celecoxib solubility. Drug Dev Ind Pharm 2011;37:1463-72.
52. Huang JJ, Wigent RJ, Schwartz JB. Nifedipine molecular dispersion in microparticles of ammonio methacrylate copolymer and ethylcellulose binary blends for controlled drug delivery: effect of matrix composition. Drug Dev Ind Pharm 2006;32:1185-97.
53. Chen J, Qiu LY, Hu MX, et al. Preparation, characterization and in vitro evaluation of solid dispersions containing docetaxel. Drug Dev Ind Pharm 2008;34:588-94.
54. Kestur US, Taylor LS. Role of polymer chemistry in influencing crystal growth rates from amorphous felodipine. CrystEngComm 2010;12:2390-7.
55. Thybo P, Kristensen J, Hovgaard L. Characterization and physical stability of tolfenamic acid-pvp k30 solid dispersions. Pharm Dev Technol 2007;12:43-53.
56. Laurence C, Brameld KA, Graton J, et al. The pKBHX database: toward a better understanding of hydrogen-bond basicity for medicinal chemists. J Med Chem 2009;52:4073-86.
57. Lu T, Shan G, Shang S. Intermolecular interaction in aqueous solution of binary blends of poly(acrylamide) and poly(ethylene glycol). J Appl Polym Sci 2010;118:2572-81.
58. Van Eerdenbrugh B, Taylor LS. An ab initio polymer selection methodology to prevent crystallization in amorphous solid dispersions by application of crystal engineering principles. CrystEngComm 2011;13:6171-8.
59. Karavas E, Georgarakis E, Sigalas MP, et al. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Eur J Pharm Biopharm 2007;66:334-7.
60. Karavas E, Ktistis G, Xenakis A, Georgarakis E. Miscibility behavior and formation mechanism of stabilized felodipine-polyvinylpyrrolidone amorphous solid dispersions. Drug Dev Ind Pharm 2005;31:473-89.
61. Zheng X, Yang R, Tang X, Zheng LY. Part I: characterization of solid dispersions of nimodipine prepared by hot-melt extrusion. Drug Dev Ind Pharm 2004;33:791-802.
62. Huang JJ, Wigent RJ, Schwartz JB. Drug-polymer interaction and its significance on the physical stability of nifedipine amorphous dispersion in microparticles of an ammonio methacrylate copolymer and ethylcellulose binary blend. J Pharm Sci 2008;97:251-62.
63. Kreidel RN, Duque MD, Serra CHR, et al. Dissolution enhancement and characterization of nimodipine solid dispersions with poloxamer 407 or PEG 6000. J Disper Sci Technol 2012;33:1354-9.
64. Miyazaki T, Aso Y, Yoshioka S, Kawanishi T. Differences in crystallization rate of nitrendipine enantiomers in amorphous solid dispersions with HPMC and HPMCP. Int J Pharm 2011;407:111-18.
65. Huang JJ, Li Y, Wigent RJ, et al. Interplay of formulation and process methodology on the extent of nifedipine molecular dispersion in polymers. Int J Pharm 2011;420:59-67.
66. Chan KLA, Kazarian SG. FTIR spectroscopic imaging of dissolution of a solid dispersion of nifedipine in poly(ethylene glycol). Mol Pharm 2004;1:331-5.
67. Qi S, Belton P, Nollenberger K, et al. Compositional analysis of low quantities of phase separation in hot-melt-extruded solid dispersions: a combined atomic force microscopy, photothermal fourier-transform infrared microspectroscopy, and localised thermal analysis approach. Pharm Res 2011;28:2311-26.
68. Konno H, Taylor LS. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture. Pharm Res 2008;25:969-78.
69. Marsac PJ, Konno H, Taylor LS. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm Res 2006;23:2306-16.
70. Tang XLC, Pikal MJ, Taylor LS. The effect of temperature on hydrogen bonding in crystalline and amorphous phases in dihydropyrine calcium channel blockers. Pharm Res 2002;19:484-490.
71. Rumondor ACF, Ivanisevic I, Bates S, et al. Evaluation of drugpolymer miscibility in amorphous solid dispersion systems. Pharm Res 2009;26:2523-34.
72. Verheyen S, Blaton N, Kinget R, Van den Mooter G. Mechanism of increased dissolution of diazepam and temazepam from polyethylene glycol 6000 solid dispersions. Int J Pharm 2002;249:45-58.